Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02975271 · ClinicalTrials.gov registry record · Phase 2
Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury
A Phase 2 study, sponsored by Vyne Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02975271 is a Phase 2 study that was terminated before completion, run by Vyne Therapeutics. The registered enrollment target is 1 participants.
The verdict
NCT02975271, a Phase 2 study, was terminated before completion, sponsored by Vyne Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
Study of the Efficacy, Safety \& Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury
Interventions
- DRUG Placebo
- DRUG Serlopitant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-11 |
| Est. Completion | 2017-01-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02975271
The ClinicalTrials.gov registry entry for NCT02975271 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vyne Therapeutics, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02975271 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02975271 about?
NCT02975271 is a clinical study titled "Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury". Study of the Efficacy, Safety \& Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury
What is the current status of trial NCT02975271?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2016-11. Estimated completion is 2017-01-17.
What interventions are being tested in trial NCT02975271?
The interventions under investigation include: Placebo (DRUG), Serlopitant (DRUG).
Who is sponsoring clinical trial NCT02975271?
This trial is sponsored by Vyne Therapeutics, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.